Entresto (Sacubitril/Valsartan) Provides Superior Mortality and Hospitalization Benefits Compared to Ramipril in Heart Failure with Reduced Ejection Fraction
For patients with symptomatic heart failure with reduced ejection fraction (HFrEF), sacubitril/valsartan (Entresto) is superior to ACE inhibitors like ramipril, reducing cardiovascular death by 20% and heart failure hospitalizations by 21% compared to enalapril (a comparable ACE inhibitor to ramipril). 1
Key Clinical Benefits
Mortality and Hospitalization Reduction
The landmark evidence demonstrates that sacubitril/valsartan reduces:
- Combined cardiovascular death or HF hospitalization by 20% (hazard ratio 0.80,95% CI 0.73-0.87) 2
- All-cause mortality by 16% (hazard ratio 0.84,95% CI 0.76-0.93) 2
- Heart failure hospitalizations by 21% compared to enalapril 1
These benefits are consistent across patients with and without hypertension, and across varying baseline blood pressure levels 2.
Cardiac Reverse Remodeling
Sacubitril/valsartan produces superior cardiac structural improvements compared to ACE inhibitors:
- 42% increase in left ventricular ejection fraction at 1 year 3
- 18% reduction in left ventricular end-diastolic volume 3
- 32% reduction in left ventricular end-systolic volume 3
- 35% reduction in functional mitral regurgitation (EROA decreased from 0.36 to 0.24 cm²) 3
Neurohormonal Benefits
Sacubitril/valsartan achieves greater neurohormonal modulation:
- 47% reduction in NT-proBNP at 4 weeks versus 25% with enalapril 4
- This biomarker reduction correlates with improved clinical outcomes 4
Guideline Recommendations
Multiple international guidelines now recommend sacubitril/valsartan as replacement therapy for ACE inhibitors/ARBs in appropriate HFrEF patients:
ESC Guidelines (2016)
Sacubitril/valsartan receives a Class I, Level B recommendation as replacement for ACE inhibitors to further reduce HF hospitalization and death in ambulatory HFrEF patients who remain symptomatic despite optimal treatment with ACE inhibitor, beta-blocker, and mineralocorticoid receptor antagonist 5.
ACC/AHA Guidelines (2016)
The clinical strategy of renin-angiotensin system inhibition with ARNI (sacubitril/valsartan) receives Class I, Level B-R recommendation in conjunction with beta-blockers and aldosterone antagonists for chronic HFrEF to reduce morbidity and mortality 1.
Canadian Guidelines (2021)
ARNI therapy is established as a well-supported treatment recommendation, with evidence supporting both:
- Replacement of existing ACE inhibitor/ARB therapy in chronic HFrEF 4
- First-line use in de novo (newly diagnosed) HFrEF, where patients achieved target dose more frequently (56% vs 45%) with fewer serious adverse reactions 4
Patient Selection Criteria
Initiate sacubitril/valsartan in patients meeting these criteria:
- LVEF ≤40% (or below normal based on clinical judgment) 6
- NYHA Class II-IV symptoms despite optimal medical therapy 5
- Currently tolerating ACE inhibitor or ARB at adequate doses 1
- Systolic blood pressure ≥100 mmHg (to minimize hypotension risk)
- eGFR ≥30 mL/min/1.73m² 2
- Potassium ≤5.4 mEq/L (to minimize hyperkalemia risk)
Critical Safety Considerations
Mandatory Washout Period
Allow 36 hours between discontinuing ACE inhibitor and starting sacubitril/valsartan to prevent angioedema 1, 6. This is an absolute requirement, not a suggestion.
Contraindications
- History of angioedema with ACE inhibitor or ARB 6
- Concomitant ACE inhibitor use 6
- Pregnancy (discontinue immediately if detected) 6
- Concomitant aliskiren in diabetic patients 6
Common Adverse Effects
Monitor for:
- Hypotension (most common, up to 17.6% in real-world data) 7
- Hyperkalemia (≥5% incidence) 6
- Renal dysfunction (≥5% incidence) 6
- Cough and dizziness (≥5% each) 6
Real-world evidence confirms that severe hyperkalemia and renal decline occur at similar rates compared to traditional ACE inhibitors/ARBs 7.
Dosing Strategy
Start at 49/51 mg twice daily (or 24/26 mg twice daily if not currently on ACE inhibitor/ARB, or if severe renal impairment/moderate hepatic impairment) 6.
Double the dose every 2-4 weeks to target maintenance dose of 97/103 mg twice daily, as tolerated 6.
Real-world data shows only 15-25% of patients achieve target doses in clinical practice 7, representing a significant implementation gap that should be addressed through systematic titration protocols.
Comparison to Ramipril Specifically
While the pivotal PARADIGM-HF trial compared sacubitril/valsartan to enalapril (not ramipril directly), ramipril and enalapril are considered therapeutically equivalent ACE inhibitors at comparable doses (ramipril 5 mg twice daily = enalapril 10 mg twice daily) 8.
The PARADISE-MI study directly compared sacubitril/valsartan to ramipril in post-MI patients with LV dysfunction, showing a non-significant 10% reduction in cardiovascular death or HF episodes, though sacubitril/valsartan was more effective in preventing recurrent HF after the first episode 9. This suggests the benefit may be most pronounced in established chronic HFrEF rather than acute post-MI settings.
Meta-analysis confirms that when compared to equivalent doses of ACE inhibitors, sacubitril/valsartan shows superior outcomes 10. The mortality and hospitalization benefits are most evident when replacing sub-equivalent ACE inhibitor doses, but the totality of evidence supports superiority even at equivalent dosing when considering the full spectrum of outcomes including reverse remodeling and biomarker improvements.
Clinical Bottom Line
Replace ramipril with sacubitril/valsartan in symptomatic HFrEF patients (LVEF ≤40%, NYHA II-IV) who remain symptomatic despite optimal medical therapy. The evidence for mortality reduction, hospitalization prevention, and cardiac reverse remodeling is robust and consistent across multiple high-quality guidelines 1, 5, 4. Ensure 36-hour ACE inhibitor washout, start at appropriate dose based on patient characteristics, and systematically titrate to target dose while monitoring blood pressure, renal function, and potassium.